Eli Lilly's $75M Payment Drives MeiraGTx's Revenue Surge, Narrowing 2025 Loss
MGTX sits 71% above its 52-week low of $4.55.
Summary
MeiraGTx Holdings reported a significantly narrowed net loss for 2025, primarily driven by a surge in revenue. This revenue increase was largely due to a $75 million upfront payment received from Eli Lilly for the AAV-AIPL1 program and related assets. The company also announced it possesses sufficient capital to fund its operations into the second half of 2027, excluding potential milestone payments. This positive financial update, highlighted by the substantial collaboration payment and extended cash runway, is a material development for the gene therapy firm and provides a more stable outlook for investors.
At the time of this announcement, MGTX was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $613.3M. The 52-week trading range was $4.55 to $9.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.